AIMT - Will Vaping Deaths Derail Marijuana Stocks? Plus a New Treatment for Peanut Allergies Advances
A wave of vaping-related illnesses has resulted in hundreds of visits to hospitals and at least seven deaths in the United States. Investigators have yet to determine exactly what about vaping is causing these life-threatening symptoms, but there's a good chance that industry changes, including regulation, are coming. In this episode of The Motley Fool's Industry Focus: Healthcare, analyst Shannon Jones and contributor Todd Campbell discuss what changes could mean to cannabis companies' future sales.
Also, Aimmune Therapeutics (NASDAQ: AIMT) recently won key support for approval of its medicine for peanut allergies, Palforzia. A standardized approach that could help reduce reactions to accidental exposure to peanuts in kids and teens, Palforzia aims to desensitize patients to peanuts through controlled exposure to peanut proteins that cause allergic reactions. Can this medicine reshape treatment or will safety concerns limit its risk?
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.